INFAI Institut fir Biomedizinische Analytik und NMR Imaging GmbH – Trademark Portfolio

Entity Type: 16

INFAI Institut fir Biomedizinische Analytik und NMR Imaging GmbH holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. The owner is based in 44799 Bochum.

Universititsstrasse 142

44799 Bochum , DE

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

INFAI Institut fir Biomedizinische Analytik und NMR Imaging GmbH's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does INFAI Institut fir Biomedizinische Analytik und NMR Imaging GmbH have?

INFAI Institut fir Biomedizinische Analytik und NMR Imaging GmbH has 1 U.S. trademark filed with the USPTO.

What trademark classes does INFAI Institut fir Biomedizinische Analytik und NMR Imaging GmbH file in?

INFAI Institut fir Biomedizinische Analytik und NMR Imaging GmbH files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What is INFAI Institut fir Biomedizinische Analytik und NMR Imaging GmbH's trademark registration success rate?

INFAI Institut fir Biomedizinische Analytik und NMR Imaging GmbH has a 0% trademark registration rate, with 0 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.